The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation.

The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation.
复制标题

ATM 和 ATR 激酶通过靶向 KIFC1 磷酸化来调节中心体聚类和肿瘤复发。

DOI:
10.1038/s41467-020-20208-x
复制
发表时间:
2021-01-04
影响因子:
16.6
通讯作者:
Wang C
Wang C
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Fan G;Sun L;Meng L;Hu C;Wang X;Shi Z;Hu C;Han Y;Yang Q;Cao L;Zhang X;Zhang Y;Song X;Xia S;He B;Zhang S;Wang C

文献摘要

参考文献

被引文献

相似文献

耐药性和肿瘤复发是癌症治疗中的重大挑战。癌细胞常常表现出中心体扩增。为维持生存,癌细胞通过将多余的中心体聚集来实现双极分裂。因此,靶向中心体聚集被视为一种有前景的治疗策略。然而,中心体聚集的调控机制仍不明确。在此我们报告,中心体聚集调节因子KIFC1与肿瘤复发呈正相关。在DNA损伤治疗下,ATM和ATR激酶使KIFC1的丝氨酸26位点发生磷酸化,通过中心体聚集选择性维持中心体扩增的癌细胞的存活,从而导致耐药性和肿瘤复发。抑制KIFC1的磷酸化可抑制中心体聚集和肿瘤复发。本研究确定KIFC1为一种预测肿瘤复发的标志物,并揭示肿瘤在DNA损伤应激下可通过触发中心体聚集获得治疗抗性和复发能力,这表明阻断KIFC1的磷酸化可能为癌症治疗开辟新前景。 中心体聚集是癌症中有前景的治疗靶点,但其调控方式仍不明确。在此,作者表明,作为对DNA损伤的响应,ATM/ATR使中心体聚集调节因子KIFC1稳定,从而提高聚集效率并导致肿瘤复发。
Drug resistance and tumor recurrence are major challenges in cancer treatment. Cancer cells often display centrosome amplification. To maintain survival, cancer cells achieve bipolar division by clustering supernumerary centrosomes. Targeting centrosome clustering is therefore considered a promising therapeutic strategy. However, the regulatory mechanisms of centrosome clustering remain unclear. Here we report that KIFC1, a centrosome clustering regulator, is positively associated with tumor recurrence. Under DNA damaging treatments, the ATM and ATR kinases phosphorylate KIFC1 at Ser26 to selectively maintain the survival of cancer cells with amplified centrosomes via centrosome clustering, leading to drug resistance and tumor recurrence. Inhibition of KIFC1 phosphorylation represses centrosome clustering and tumor recurrence. This study identified KIFC1 as a prognostic tumor recurrence marker, and revealed that tumors can acquire therapeutic resistance and recurrence via triggering centrosome clustering under DNA damage stresses, suggesting that blocking KIFC1 phosphorylation may open a new vista for cancer therapy.
DOI: 10.1038/nature05268
发表时间: 2006-11-30
期刊: NATURE
影响因子: 64.8
作者:
Bartkova, Jirina;Rezaei, Nousin;Gorgoulis, Vassilis G.
通讯作者: Gorgoulis, Vassilis G.
DOI: 10.1016/j.cmet.2013.08.012
发表时间: 2013-09-03
期刊: Cell metabolism
影响因子: 29
作者:
Dong S;Jia C;Zhang S;Fan G;Li Y;Shan P;Sun L;Xiao W;Li L;Zheng Y;Liu J;Wei H;Hu C;Zhang W;Chin YE;Zhai Q;Li Q;Liu J;Jia F;Mo Q;Edwards DP;Huang S;Chan L;O'Malley BW;Li X;Wang C
通讯作者: Wang C
DOI: 10.7150/ijbs.7.1122
发表时间: 2011
影响因子: 9.2
作者:
Chan JY
通讯作者: Chan JY
KLF14 缺失会触发中心体扩增和肿瘤发生
DOI: 10.1038/ncomms9450
发表时间: 2015-10-06
影响因子: 16.6
作者:
Fan G;Sun L;Shan P;Zhang X;Huan J;Zhang X;Li D;Wang T;Wei T;Zhang X;Gu X;Yao L;Xuan Y;Hou Z;Cui Y;Cao L;Li X;Zhang S;Wang C
通讯作者: Wang C
DOI: 10.1091/mbc.e08-09-0971
发表时间: 2009-03-01
影响因子: 3.3
作者:
Cai, Shang;Weaver, Lesley N.;Walczak, Claire E.
通讯作者: Walczak, Claire E.